A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.

Trial Profile

A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Carcinomatous meningitis; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 01 Aug 2017 Results published in the Anticancer Research
    • 01 Aug 2017 Status changed from recruiting to active, no longer recruiting as per results published in the Anticancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top